Celldex Therapeutics (NASDAQ:CLDX) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX) in a report issued on Thursday morning,Benzinga reports. They currently have a $80.00 price objective on the biopharmaceutical company’s stock.

CLDX has been the subject of several other research reports. Wolfe Research lowered shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research note on Friday, September 27th. Citigroup began coverage on shares of Celldex Therapeutics in a report on Monday, October 7th. They issued a “buy” rating and a $70.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research note on Monday, September 16th. The Goldman Sachs Group started coverage on Celldex Therapeutics in a report on Monday, September 30th. They issued a “neutral” rating and a $45.00 price objective on the stock. Finally, Wells Fargo & Company raised Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 26th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $62.25.

Celldex Therapeutics Trading Down 0.5 %

CLDX stock traded down $0.14 during trading on Thursday, reaching $26.33. 410,340 shares of the stock were exchanged, compared to its average volume of 868,227. The firm has a market capitalization of $1.75 billion, a price-to-earnings ratio of -10.37 and a beta of 1.60. The business has a 50 day moving average price of $33.90 and a 200-day moving average price of $35.90. Celldex Therapeutics has a 1 year low of $24.43 and a 1 year high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.05. Celldex Therapeutics had a negative return on equity of 20.41% and a negative net margin of 1,544.32%. The firm had revenue of $3.19 million for the quarter, compared to analysts’ expectations of $1.44 million. On average, research analysts anticipate that Celldex Therapeutics will post -2.5 EPS for the current year.

Institutional Investors Weigh In On Celldex Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. KBC Group NV raised its holdings in Celldex Therapeutics by 31.2% during the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 495 shares in the last quarter. GSA Capital Partners LLP raised its stake in Celldex Therapeutics by 191.2% during the 3rd quarter. GSA Capital Partners LLP now owns 16,114 shares of the biopharmaceutical company’s stock worth $548,000 after acquiring an additional 10,581 shares in the last quarter. Emerald Advisers LLC lifted its position in Celldex Therapeutics by 129.9% in the third quarter. Emerald Advisers LLC now owns 456,202 shares of the biopharmaceutical company’s stock valued at $15,506,000 after acquiring an additional 257,773 shares during the last quarter. Emerald Mutual Fund Advisers Trust boosted its stake in Celldex Therapeutics by 92.0% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 243,795 shares of the biopharmaceutical company’s stock valued at $8,287,000 after acquiring an additional 116,832 shares in the last quarter. Finally, Novo Holdings A S increased its position in shares of Celldex Therapeutics by 13.4% during the third quarter. Novo Holdings A S now owns 963,663 shares of the biopharmaceutical company’s stock worth $32,755,000 after purchasing an additional 113,663 shares in the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.